Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

N/A

DAYTRANA 31.8 - N/A N/A

GI

PENTASA 84.0 62.6 +34 +6

LIALDA 5.0 - N/A N/A

RENAL

FOSRENOL 47.3 13.9 N/A +12

DYNEPO 1.9 - N/A N/A

1.1.1.1.6GP

CALCICHEW 25.6 22.1 +16 N/A

CARBATROL 33.4 30.3 +10 -5

REMINYL/REMINYL XL 14.6 9.3 +57 N/A

XAGRID 31.6 26.2 +21 N/A

Other product

sales 52.6 57.8 -9

__________ __________ __________

832.0 667.9 +25

__________ __________ __________

Human Genetic

Therapies

REPLAGAL 64.4 54.1 +19 N/A

ELAPRASE 69.3 - N/A N/A

__________ __________ __________

133.7 54.1 N/A

__________ __________ __________

Total product sales

965.7 722.0 +34

__________ __________ __________

The following discussion includes references to prescription and market share data for Shire's key products. The source of this data is IMS Health, June 2007. IMS Health is a leading global provider of business intelligence for the pharmaceutical and healthcare industries.

ADDERALL XR

ADDERALL XR is the leading brand in the US ADHD market with an average market share of 26% during the six months to June 30, 2007 (2006: 26%). US ADHD market growth of
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/18/2014)... -- Cord Blood Registry® (CBR®) announces that the ... Stem Cell Summit, the largest global meeting of stem cell ... Summit will be held December 3-5 at the Marriott Rivercenter ... The World Stem Cell Summit aims to ... convening the most prominent figures in the field to share ...
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – featuring ... professor in the Regulatory Biology Laboratory at the Salk Institute, ... to an “off switch” for drug resistance in cancer. , ... research is making a global impact in the fight against ... host Cheryl K. Goodman, CEO of Social Global Mobile LLC, ...
(Date:11/18/2014)... 18, 2014 2014 Deep ... is professional and in-depth report on Polytetrahydrofuran ... information, including its definition, characterization, application, and ... This exploration covers the worldwide business investigation, ... examination covering macroeconomic environment & financial circumstance ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... in Cancer Stem Cell Biology Enhances, MacroGenics, Oncology Capabilities ... ... Platforms, ROCKVILLE, Md., July 17 MacroGenics, Inc., a ... and infectious diseases, today announced the,acquisition of Raven Biotechnologies, Inc., ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI), today announced ... Board has changed from "LRRI.OB" to "ARNI.OB",effective July ... Therapeutics, Inc. is a clinical-stage biopharmaceutical company,that develops ... patients. Arno,s lead compound is AR-67, a novel, ...
... 17 Following intense,speculation in sections of ... Sankyo,Company, Limited (TSE: 4568.JP) ("Daiichi Sankyo") and ... the agreement,between Daiichi Sankyo, Ranbaxy and the ... is binding and final, subject to,regulatory approvals., ...
Cached Biology Technology:MacroGenics Acquires Raven Biotechnologies 2MacroGenics Acquires Raven Biotechnologies 3Arno Therapeutics Announces New Ticker Symbol 2Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2
(Date:11/4/2014)... 5, 2014 – University of Utah engineers developed the ... jet fuel produce electricity without needing to ignite the ... power portable electronics, off-grid power and sensors. , A ... the American Chemical Society journal ACS Catalysis . ... chemical reaction between a fuel and an oxygen-rich source ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... 3, 2014  NeuroSigma ® , Inc. (NeuroSigma), ... company focused on commercialization of its non-invasive ... treatment of neurological and neuropsychiatric disorders, announced today ... issued a Notice of Allowance for Mexican Patent ... by NeuroSigma and the Regents of the University ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... CA Researchers from all over the world will be ... Department of Energy Joint Genome Institute 6th Annual Meeting, ... clean energy generation and the environment. Keynote speeches will ... Linear Accelerator Center, and microbial ecologist Terry Hazen of ...
... March 9, 2011 ActiveRx Rehabilitation , a ... working with senior adults, is now available to franchisees ... active aging. ActiveRx Development Company, Inc., based ... qualified operators interested in single or multi-location opportunities and ...
... - Hybrid plants with multiple genome copies show evidence of ... the genes of the other parent, even to the point ... Brian Dilkes, an assistant professor of genetics at Purdue University, ... California Davis and University of Southern California to study the ...
Cached Biology News:New Healthcare Franchise Opportunity Focuses on Treating Exploding Senior Population 2Study shows how plants sort and eliminate genes over millennia 2
Request Info...
Makes gels easy to load and track during electrophoresis. 10X concentrate of Bromophenol Blue, Xylene Cyanol, glycerol solution in TE...
Request Info...
Request Info...
Biology Products: